Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older at the time of signing the consent form
• People who have melanoma that cannot be surgically removed or has spread to other parts of the body
• People who have melanoma (not originating in the eye/uvea) where the disease continued to grow or spread during or within 12 weeks after receiving a specific type of immunotherapy (a PD-1/PD-L1 blocking antibody); if the melanoma has a specific gene change called BRAF V600, prior treatment with a BRAF inhibitor (with or without a MEK inhibitor) must also have been received or refused
• For one specific part of the trial only (Phase 1, Part 1): People with uveal (eye) melanoma where a treatment called tebentafusp was received if it was available as a standard treatment for that person, or refused
• People whose general health and activity level is rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity), and who are expected by their doctor to live more than 6 months
• For one specific part of the trial only (Phase 1, Part 2): People who, after a tumour removal procedure used to generate a treatment called lifileucel, still have at least one measurable tumour remaining
• People who have recovered from side effects of any previous cancer treatments

Who may not be able to join:

• People who have brain metastases (cancer that has spread to the brain) that are causing symptoms and have not been treated
• People who are considered at increased risk for serious infections, or who have seizure disorders, blood clotting disorders, or significant active illnesses affecting the heart, lungs, or immune system
• People who have active uveitis (inflammation inside the eye) that currently requires treatment
• People who have a primary immune system disorder (such as severe combined immunodeficiency or AIDS)
• People who have had an allergic reaction to any ingredient in the study treatment
• People who have had another separate cancer diagnosis within the past 3 years
• People who currently need daily steroid medication at a dose of 10 mg or more of prednisone (or an equivalent steroid)
• People who have a history of receiving an organ transplant from another person, or who have undergone any cell-based therapy that required chemotherapy preparation within the past 20 years

Important: Always verify eligibility with the trial site directly before applying.